MA48602A - Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha - Google Patents

Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha

Info

Publication number
MA48602A
MA48602A MA048602A MA48602A MA48602A MA 48602 A MA48602 A MA 48602A MA 048602 A MA048602 A MA 048602A MA 48602 A MA48602 A MA 48602A MA 48602 A MA48602 A MA 48602A
Authority
MA
Morocco
Prior art keywords
modulators
phosphine oxide
compounds substituted
ifn alpha
heteroaryl compounds
Prior art date
Application number
MA048602A
Other languages
English (en)
Inventor
John V Duncia
David S Weinstein
Zili Xiao
Michael G Yang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA48602A publication Critical patent/MA48602A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA048602A 2016-12-13 2017-12-12 Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha MA48602A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662433470P 2016-12-13 2016-12-13

Publications (1)

Publication Number Publication Date
MA48602A true MA48602A (fr) 2020-03-18

Family

ID=60888685

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048602A MA48602A (fr) 2016-12-13 2017-12-12 Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha

Country Status (10)

Country Link
US (1) US10294256B2 (fr)
EP (1) EP3555111B1 (fr)
JP (1) JP7046092B2 (fr)
KR (1) KR102602558B1 (fr)
CN (1) CN110267964B (fr)
AR (1) AR110351A1 (fr)
ES (1) ES2907008T3 (fr)
MA (1) MA48602A (fr)
TW (1) TW201827423A (fr)
WO (1) WO2018111787A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL274816B2 (en) 2017-11-21 2023-12-01 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
EP3768667B1 (fr) * 2018-03-22 2023-04-12 Bristol-Myers Squibb Company Composés hétérocycliques comprenant de la pyridine utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
WO2021143498A1 (fr) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 Forme cristalline de deucravacitinib, son procédé de préparation et son utilisation
CN115160297B (zh) 2020-12-22 2023-03-31 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
CN114805438A (zh) * 2021-01-18 2022-07-29 正大天晴药业集团股份有限公司 含磷酰基的tyk2抑制剂化合物
CN117083268B (zh) 2021-03-16 2024-07-30 安锐生物医药科技(广州)有限公司 氨基杂芳基化合物和组合物
CN115724830A (zh) * 2021-08-31 2023-03-03 浙江文达医药科技有限公司 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
EP4423086A1 (fr) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Agents de dégradation de tyk2 et leurs utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270730A1 (en) 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
EP2300013B2 (fr) * 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Dérivés phosphorés servant d'inhibiteurs de kinase
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CN104125947A (zh) * 2011-12-21 2014-10-29 生物区欧洲有限公司 杂环脲化合物
JP6469567B2 (ja) * 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Egfr発動性がんの細胞増殖阻害用化合物
AU2013341186B2 (en) 2012-11-08 2017-03-30 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
AR093403A1 (es) 2012-11-08 2015-06-03 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
WO2014181287A1 (fr) * 2013-05-09 2014-11-13 Piramal Enterprises Limited Composés hétérocyclyliques et leurs utilisations
AR094537A1 (es) * 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
EP2947460A1 (fr) 2014-05-22 2015-11-25 Medizinische Universität Wien Thérapie personnalisée de cancer associé à une inflammation à l'aide de procédés d'évaluation de la susceptibilité d'un sujet pour le traitement avec des antagonistes/inhibiteurs EGFR

Also Published As

Publication number Publication date
TW201827423A (zh) 2018-08-01
AR110351A1 (es) 2019-03-20
JP2020502268A (ja) 2020-01-23
US10294256B2 (en) 2019-05-21
CN110267964A (zh) 2019-09-20
KR102602558B1 (ko) 2023-11-14
CN110267964B (zh) 2022-05-03
US20180162889A1 (en) 2018-06-14
EP3555111A1 (fr) 2019-10-23
ES2907008T3 (es) 2022-04-21
EP3555111B1 (fr) 2022-01-26
JP7046092B2 (ja) 2022-04-01
KR20190091536A (ko) 2019-08-06
WO2018111787A1 (fr) 2018-06-21

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MA46453A (fr) Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha
MA46620A (fr) Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
IL256614B (en) Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated diseases
EP3524603A4 (fr) Inhibiteur de fgfr4, son procédé de préparation et son utilisation pharmaceutique
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
EP3488361A4 (fr) Système d'enregistrements de correspondance
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112018011709A2 (pt) inibidores bicíclicos de pad4
MX2017003359A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
EP3452407A4 (fr) Méthodes et utilisations aux fins de mesures d'activité protéasique déclenchées à distance
DK3240538T3 (da) Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose
BR112016016274A2 (pt) Ponte da barreira hematoencefálica
EP3602528A4 (fr) Dispositif d'apprentissage de simulation de piston de seringue pré-rempli
EP3790461C0 (fr) Systèmes de canule de détection
EP3875542A4 (fr) Composition d'émulsion de silicone
BR112018005208A2 (pt) Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana
EP3528813A4 (fr) Composés p2x3 et/ou p2x2/3 et méthodes associées
CL2016001763A1 (es) Antagonistas selectivos de nr2b
MY192425A (en) Polymorphs
EP3551612A4 (fr) Procédé de préparation de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophényl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate et ses polymorphes
EP3328368A4 (fr) Composés et composition pharmaceutique associée au système d'ubiquitination-protéasome
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP3793550A4 (fr) Composés 2,2'-bipyrimidinyl substitués, analogues de ceux-ci, et procédés les utilisant